CellSource Co (TSE:4880) ROC %: 7.88% (As of Apr. 2026)


TSE:4880 CellSource Co Ltd TSE:4880
69 GF Score
Price 円319.00
GF Value 円781.48
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CellSource Co ROC %?

CellSource Co TSE:4880 -2.15% 69 ROC % is 7.88% as of Apr. 2026. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. CellSource Co's annualized return on capital (ROC %) for the quarter that ended in Apr. 2026 was 7.88%.

As of today (2026-07-09), CellSource Co's WACC % is 3.70%. CellSource Co's ROC % is 4.51% (calculated using TTM income statement data). CellSource Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


CellSource Co  (TSE:4880) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, CellSource Co's WACC % is 3.70%. CellSource Co's ROC % is 4.51% (calculated using TTM income statement data). CellSource Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


CellSource Co ROC % Related Terms


CellSource Co ROC % Historical Data

* Premium members only.

The historical data trend for CellSource Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSource Co ROC % Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
ROC %
Get a 7-Day Free Trial Premium Member Only 146.74 160.28 69.76 4.72 0.69

CellSource Co Semi-Annual Data
Oct17 Oct18 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.79 -5.70 0.66 0.00 7.88
TSE:4880
69GF Score
CellSource Co Ltd TSE:4880
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellSource Co ROC % Calculation

CellSource Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2025 is calculated as:

ROC % (A: Oct. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2024 ) + Invested Capital (A: Oct. 2025 ))/ count )
=166.708 * ( 1 - 90.3% )/( (2555.558 + 2151.209)/ 2 )
=16.170676/2353.3835
=0.69 %

where

Invested Capital(A: Oct. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7074.909 - 198.436 - ( 4320.915 - max(0, 441.592 - 5068.814+4320.915))
=2555.558

Invested Capital(A: Oct. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7023.969 - 160.94 - ( 4711.82 - max(0, 442.839 - 5487.599+4711.82))
=2151.209

CellSource Co's annualized Return on Capital (ROC %) for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=251.426 * ( 1 - 34.28% )/( (2151.209 + 2042.975)/ 2 )
=165.2371672/2097.092
=7.88 %

where

Invested Capital(Q: Oct. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7023.969 - 160.94 - ( 4711.82 - max(0, 442.839 - 5487.599+4711.82))
=2151.209

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6984.466 - 154.96 - ( 4786.531 - max(0, 499.951 - 5482.147+4786.531))
=2042.975

Note: The Operating Income data used here is two times the semi-annual (Apr. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 7.88% mean?
CellSource Co (TSE:4880) has a ROC % of 7.88% as of Apr. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on CellSource Co and its competitors.
Is CellSource Co's ROC % too high?
CellSource Co's current ROC % is 7.88%. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's ROC % compare to VRTX and REGN?
CellSource Co's ROC % of 7.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on CellSource Co and its competitors. CellSource Co's current ROC % is 7.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current ROC % is 7.88%. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current ROC % is 7.88% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSource Co (TSE:4880) Overvalued in 2026?

Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued. The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48. GuruFocus considers CellSource Co to be Significantly Undervalued.

Key valuation signals for TSE:4880:

  • ROC %: 7.88%
  • GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CellSource Co Business Description

Address Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score

Get the complete analysis for TSE:4880

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円319.00
Price
円781.48
GF Value